Samsara BioCapital — 2024 Investments
4 investments dated 2024 · listed companies and verified rows first · show all
vTv Therapeutics is a biopharmaceutical company developing oral, small molecule drugs for diabetes and other chronic diseases.
BiotechDigital HealthMedical DevicesHigh Point, US
Rudy Howard(Executive Officer)Paul Meister(Director)Stephen Holcombe(Executive Officer)Paul Savas(Director)Noel Spiegel(Director)Howard Weiner(Director)
Board seatSrinivas Akkaraju· per SEC Form D
HealthtechSan Francisco, US
James Tananbaum(Director)June Lee(Executive Officer, Director)
BoardVikram Bajaj(Director)
Board seatSrinivas Akkaraju· per SEC Form D · $40M raise · filed Jul 2024
Autobahn develops medicines for central nervous system (CNS) disorders by leveraging regenerative mechanisms of the human body.
BiotechDeep TechMedical DevicesSan Diego, US
Kevin Finney(Chairman, President and CEO)John Borkholder(Executive Officer)
BoardKristina Burow(Director)Thomas Cahill(Director)Timothy Anderson(Director)Philip J DeSouza(Director)
CandidRx develops T-cell engager antibodies to treat autoimmune diseases by redirecting T-cells to eliminate autoreactive B-cells.
BiotechHealthtechSan Diego, US
Ken Song(Chairman, President and CEO)Kenneth Song, M.D.(Executive Officer, Director)Arvind Kush(Executive Officer)Timothy Lu, M.D.(Executive Officer)Bernie Huyghe, Ph.D.(Executive Officer)
BoardJeffrey Tong, Ph.D.(Director)
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.